Neuromodulation in Neuropsychiatric Disorders: November 2016

3.00 CME
180 MINS
$30 FEE
SAVE
Psych Annals November 2016 Cover

Overview

Table of Contents

Overview of the Current Use of Deep Brain Stimulation in Psychiatric Disorders

Daniel P. Witter, MD, PhD; and Herbert E. Ward, MD

Update on Transcranial Magnetic Stimulation for Depression and Other Neuropsychiatric Illnesses

Jonathan E. Becker, DO, MS; Christopher Maley, MD; Elizabeth Shultz, DO; and Warren D. Taylor, MD, MHSc

Transcranial Direct Current Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review

Sarah M. Szymkowicz, MS; Molly E. McLaren, MS; Uma Suryadevara, MD; and Adam J. Woods, PhD

Charting the Course of Electroconvulsive Therapy: Where Have We Been and Where Are We Headed?

Peter B. Rosenquist, MD; W. Vaughn McCall, MD, MS; and Nagy Youssef, MD


Sponsorship Statement

This CME activity is jointly sponsored by Keck School of Medicine of USC and Psychiatric Annals.


Support Statement

There is no commercial support for this activity.


Learning Objectives

1. Discuss recent research using deep brain stimulation in psychiatric disorders.

2. Describe the current US Food and Drug Administration-approved indications for transcranial magnetic stimulation.

3. Recognize the efficacy of transcranial direct current stimulation in different psychiatric disorders.

4. Describe how changes in electroconvulsive therapy have improved outcomes.

Faculty names and affiliations:  See authors above

Guest Editor: Khurshid A. Khurshid, MD, FAASM

Reviewer names:  Jan Fawcett, MD, Editor, Psychiatric Annals; Andrew A. Nierenberg, MD, CME Coordinator, Psychiatric Annals


Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue and also on this page.

Faculty members report the following financial relationships:   Jan Fawcett, MD, has no relevant financial relationships to disclose. Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly and Company; EpiQ, Forest; Johnson and Johnson; Labopharm; Merck; Methylation Science; Novartis; PamLabs; PGx Health; Shire; Schering-Plough; Sunovion; Takeda/Lundbeck Pharmaceuticals; Targacept; Teva: Consultant. APSARD; Belvoir Publishing; Boston Center for the Arts; University of Texas Southwestern Dallas; Hillside Hospital; American Drug Utilization Review; American Society for Clinical Psychopharmacology; Bayamon Region Psychiatric Society; Baystate Medical Center; Canadian Psychiatric Association; Columbia University; Douglas Hospital/McGill University; IMEDEX; International Society for Bipolar Disorders; Israel Society for Biological Psychiatry; John Hopkins University; MJ Consulting; Massachusetts Association of College Counselors; Medscape; MBL Publishing; Physicians Postgraduate Press; Ryan Licht Sang Foundation; Slack Publishing; SUNY Buffalo; University of Florida; University of Miami; University of Wisconsin; University of Pisa; SciMed: Honoraria / travel expenses. Appliance Computing, Inc.; Brain Cells, Inc.: Stock options. AHRQ; Cephalon; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals; Takeda; Elan; Shire: Grant / research support.

Authors report the following financial relationships: Khurshid A. Khurshid has no relevant financial relationships to disclose. Daniel P. Witter has no relevant financial relationships to disclose. Herbert E. Ward has no relevant financial relationships to disclose. Jonathan E. Becker has no relevant financial relationships to disclose. Christopher Maley has no relevant financial relationships to disclose. Elizabeth Shultz has no relevant financial relationships to disclose. Warren D. Taylor has no relevant financial relationships to disclose. Sarah M. Szymkowicz has no relevant financial relationships to disclose. Molly E. McLaren has no relevant financial relationships to disclose. Uma Suryadevara has no relevant financial relationships to disclose. Adam J. Woods has no relevant financial relationships to disclose. Peter B. Rosenquist has no relevant financial relationships to disclose. W. Vaughn McCall receives research support from Merck & Co. and MECTA Corporation; has been a consultant for Merck & Co., Luitpold Pharmaceuticals, and Aetna Insurance; is on the speakers bureau for CME Outfitters; and receives royalties from Wolters Kluwer Health publishing. Nagy Youssef receives research support from the US Department of Veterans Affairs and August Biomedical Research; and has received CME honoraria from the Georgia Department of Behavioral Health and Developmental Disabilities.

The staff of Keck School of Medicine of USC and Psychiatric Annals have disclosed no relevant financial relationships. Signed disclosures are on file at Keck School of Medicine of USC.


Accreditation statement(s)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Keck School of Medicine of USC and SLACK Incorporated. The Keck School of Medicine of USC is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

The Keck School of Medicine of USC designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Release date:  November 1, 2016. Expiration Date:  December 1, 2019.


How to Participate

To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Keck School of Medicine of USC will issue an AMA PRA Category 1 Credit(s)™ certificate.


Target Audience

This CME activity is primarily targeted to patient-caring psychiatrists, physicians specializing in psychiatry and others allied to the field. There are no specific background requirements for participants taking this activity. Learning objectives and author disclosures are found at the beginning of each CME article.


Unlabeled and Investigational Usage Statement

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.


Copyright Statement

Copyright © 2016 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.